HIV / AIDS

A 1-month course of rifapentine plus isoniazid is non-inferior to 9 months of isoniazid alone for preventing TB in individuals with HIV, a study reports.

The new single-tablet regimen provides a safe and effective treatment option for patients with HIV.

A neural model suggests the frontal lobe is affected early on in HIV disease and the caudate/striatum area is affected when neurocognitive disorder symptoms develop.

Paul Sax, MD, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.

Susan Swindells, MBBS, provides an overview of long-acting injectable cabotegravir + rilpivirine for clinicians.

Incorporating clinical pharmacists and stewardship program oversights into PrEP models may improve the rate of retention in care.

A team of doctors at Johns Hopkins has completed the first ever living donor HIV-positive to HIV-positive kidney transplant.

Karin Bosh, PhD, explains why the opioid overdose death rate was higher in 2015 than in 2011 among people with HIV.

With a disproportionate percentage of new HIV infections occurring in young MSM, tech tools may be a way to counter this trend.

A survey of MSM and transgender women found that diverse formulations and regimens for PrEP, such as long-acting injectables and “on-demand” PrEP, could increase uptake and persistence.

Julia Marcus, PhD, MPH, provides advice for health care systems looking to implement a model to identify potential PrEP candidates.

Ava Avalos, MD, details the effects of a dolutegravir-based regimen on pregnancy.

There currently aren’t any clear guidelines for how health care providers should handle discrepant—1 positive and 1 negative—HIV test results during pregnancy.

A study of MSM suggests optimizing at-home testing for STIs and HIV could increase rates of testing, while noting a need to balance convenience with educational outreach.

Paul Drain, MD, MPH, explains how point-of-care viral load testing was successful in providing rapid results to patients in a South African-based study.

A new CDC report suggests that 80% of new HIV cases were transmitted by individuals who were unaware they had HIV or who were not receiving consistent care.

The makers of leronlimab (PRO 140) have filed the non-clinical portion of the drug’s Biologics License Application as a combination therapy for HIV with the FDA.

A communitywide HIV prevention package including in-home testing and antiretroviral therapy reduces new infections, according to a study from the HIV Prevention Trials Network.